We use cookies to deliver our online services. Details of the cookies we use and instructions on how to disable them are set out in our Cookies Policy. By using this website you agree to our use of cookies. To close this message click close.

Brands, Generics, and Hatch-Waxman-New Challenges: Unabated Controversy

24 June 20117:15 AM - 5:00 PM (EST) Washington

The Drug Price Competition and Patent Term Restoration Act of 1984, known as the Hatch-Waxman Amendments, continues to be the most litigated and generally contentious arenas of drug law. The constant array of lawsuits, petitions, and administrative challenges regarding 180-day exclusivity, patent listings, and patent-term extensions have addressed important issues during the last year, resolving some but further complicating others. This program will provide an in-depth analysis of these ongoing issues. The program will also address antitrust considerations associated with Hatch-Waxman patent and administrative challenges and the interplay between Hatch-Waxman and the newly authorized biosimilars approval pathway.

Hogan Lovells Partner David Fox will speak on patent certification and litigation on Friday, June 24 from 1:00 - 3:00 pm.

Download the PDF for more information.

The Westin City Center
1400 M Street, NW

24 June 2011
7:15 AM - 5:00 PM (EST)

Speaker list

Loading data